Determination of Regulatory Review Period for Purposes of Patent Extension; AURORA EV-ICD
Published Date: 2/6/2026
Notice
Summary
The FDA has officially set the review period for the AURORA EV-ICD, a medical device, so its patent can be extended. This means the company behind the device could get extra time to protect their invention, which might affect when generic versions can enter the market. Anyone interested has until February 6, 2026, to share their thoughts with the FDA.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
FDA Sets 1,521-Day Review Period
The FDA determined the regulatory review period for the AURORA EV-ICD is 1,521 days total (1,086 days in the testing phase and 435 days in the approval phase). That determination enables the patent owner to seek a patent-term extension (the applicant seeks either 297 or 868 days), which could affect when competing or generic versions can enter the market. The FDA is accepting comments on this determination through February 6, 2026.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in